KM-819 ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病2
17多系統萎縮症1

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05670782
(ClinicalTrials.gov)
July 19, 202221/12/2022A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants With Parkinson's DiseaseA Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KM-819 in Healthy Older Adults and Participants With Parkinson's DiseaseParkinson DiseaseDrug: KM-819;Drug: PlaceboFAScinate Therapeutics Inc.ParexelRecruiting40 YearsN/AAll330Phase 2United States
2NCT03022799
(ClinicalTrials.gov)
November 201627/12/2016Phase I, KM-819 in Healthy Subjects for Parkinson's DiseaseA First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly SubjectsParkinson's DiseaseDrug: KM-819;Drug: PlaceboKainos Medicine Inc.NULLCompleted19 Years45 YearsAll88Phase 1Korea, Republic of

17. 多系統萎縮症


臨床試験数 : 119 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05695378
(ClinicalTrials.gov)
February 27, 202322/12/2022Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System AtrophyMultiple System AtrophyDrug: KM-819;Drug: PlaceboKainos Medicine Inc.ParexelRecruiting30 Years80 YearsAll78Phase 2Korea, Republic of